A pharmaceutical company is developing a new anticancer drug that binds to the allosteric site of ribonucleotide reductase, reducing its activity without competing with the substrate (deoxyribonucleotide triphosphates). To confirm the non-competitive nature of this inhibition and rule out mixed-type inhibition, which investigation would be most appropriate?

Explanation

## Kinetic Proof of Non-Competitive Inhibition ### Why Michaelis-Menten Analysis is Definitive **Key Point:** Michaelis-Menten kinetics (or Lineweaver-Burk transformation) is the gold standard to distinguish non-competitive from mixed-type inhibition. The critical distinction is that **Vmax decreases while Km remains unchanged** in pure non-competitive inhibition. ### Kinetic Signatures | Inhibition Type | Vmax | Km | Lineweaver-Burk Pattern | |-----------------|------|-----|------------------------| | **Non-competitive** | Decreases | Unchanged | Lines intersect on x-axis (−1/Km constant) | | **Mixed-type** | Decreases | Increases | Lines intersect above or below x-axis | | **Competitive** | Unchanged | Increases | Lines intersect on y-axis | | **Uncompetitive** | Decreases | Decreases (proportionally) | Lines are parallel | ### Experimental Design for This Question 1. **Measure enzyme velocity (V) at multiple substrate concentrations** [dNTP] in the absence of inhibitor 2. **Repeat at increasing concentrations of the allosteric inhibitor** 3. **Plot Michaelis-Menten curves** (V vs [S]) for each inhibitor concentration 4. **Calculate Vmax and Km** from each curve (or use Lineweaver-Burk double reciprocal plots) 5. **Observe:** - If Vmax decreases and Km stays constant → **pure non-competitive** - If Vmax decreases and Km increases → **mixed-type** (the inhibitor has some affinity for ES complex) **High-Yield:** This kinetic approach **rules out mixed-type inhibition** because mixed-type inhibitors affect both Vmax AND Km, whereas pure non-competitive inhibitors affect only Vmax. ### Mechanism: Why Allosteric = Non-Competitive **Clinical Pearl:** Allosteric inhibitors bind to a site distinct from the active site, so they do not compete with substrate for binding. The inhibitor reduces the catalytic efficiency (Vmax) by stabilizing an inactive enzyme conformation, but substrate can still bind with the same affinity (Km unchanged). This is the hallmark of non-competitive inhibition.